AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21823383
Drug: Ondansetron (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.1 mg/kg for children < 40 kg, 4 mg for children > 40 kg)
Trial: 21823383
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline 2 ml)
Trial: 19145638
Drug: Chinese medicinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicinal herb complex (CCMH; a mixture of citronellol and extracts of G. lucidum, C. pilosula and A. sinensis)
Trial: 17306441
Drug: Docetaxel+prednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel+prednisolone (30 mg m(‐2) weekly during 5 of 6 wk + prednisolone 5 mg x 2 per os daily)
Trial: 15082979
Drug: Methylprednisolone (steroid)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (steroid)
Trial: 9824787
Drug: Tiagabine 4
RxNorm normalized name: tiaGABine 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine 4 mg twice daily
Trial: 9824787
Drug: Tiagabine 4
RxNorm normalized name: tiaGABine 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine 4 mg twice daily with Erythromycin 500 mg twice daily
Trial: 2140547
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg twice daily
Trial: 10661703
Drug: Saphenous vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saphenous vein patch angioplasty
Trial: 23549954
Drug: Intravenous pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pamidronate (0.8 ± 0.1 mg/kg per day for 3 days; cycles per year 2.0 ± 0.1; duration 7.3 ± 1.1 years; n = 5)
Trial: 16968960
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of pantoprazole
Trial: 16968960
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of pantoprazole
Trial: 9416720
Drug: M-6-G (Dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-6-G (Dosage B: 0.029 mg/kg bolus + 0.014 mg x kg(‐1) x h(‐1) infusion)
Trial: 9416720
Drug: M-6-G (Dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-6-G (Dosage C: 0.044 mg/kg bolus + 0.022 mg x kg(‐1) x h(‐1) infusion)
Trial: 9416720
Drug: Morphine (Dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (Dosage D: 0.14 mg/kg bolus + 0.05 mg x kg(‐1) x h(‐1) infusion)
Trial: 9416720
Drug: M-6-G combined
RxNorm normalized name: 6-amyl-m-cresol
DrugBank: Amylmetacresol (DB13908)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-6-G combined with morphine (Dosage E: A + D)
Trial: 12095079
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg procyclidine
Trial: 12095079
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg procyclidine
Trial: 27861362
Drug: Naloxone (3.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (3.25 mg/kg, 4 mg/mL)
Trial: 19660910
Drug: Chlorella supplementation
RxNorm normalized name: Chlorella emersonii extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorella supplementation (6.3g daily for 6 weeks)
Trial: 12499329
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg lysine x kg(‐1) x d(‐1)
Trial: 12145014
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg lysine x kg(‐1) x d(‐1)
Trial: 12145014
Drug: 28 mg
RxNorm normalized name: aspirin 228 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 mg lysine x kg(‐1) x d(‐1)
Trial: 15739214
Drug: Oral nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine
Trial: 2872429
Drug: Intravenous ritodrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ritodrine hydrochloride
Trial: 27296780
Drug: Treatment without
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment without ultrasound visual feedback
Trial: 12913401
Drug: Early eptifibatide
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early eptifibatide administration
Trial: 12913401
Drug: Both early
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both early and late eptifibatide administration
Trial: 1600595
Drug: Cyclophosphamide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (400 mg/m2 given i.v. on day -7)
Trial: 4065193
Drug: L-644,122 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-644,122 administered intravenously to healthy volunteers
Trial: 4065193
Drug: L-644,122 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-644,122 administered by mouth to mild hypertensives
Trial: 4065193
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose intravenous L-644,122
Trial: 18179758
Drug: Hospital-supervised program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-supervised program of chest physical therapy (13 patients)
Trial: 15131541
Drug: combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination therapy with low-dose tenectaplase and eptifibatide
Trial: 8583094
Drug: Ranitidine 100
RxNorm normalized name: ranitidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 100 mg i.v. every 12 h
Trial: 2147631
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg day-1
Trial: 15234277
Drug: Cevimeline, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cevimeline, 20 mg three times daily
Trial: 15234277
Drug: Cevimeline, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cevimeline, 30 mg three times daily
Trial: 7433897
Drug: Cimetidine, 400
RxNorm normalized name: Cimetidine, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 400 mg at bedtime
Trial: 30367939
Drug: Cholecalciferol supplementation
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol supplementation (100,000 IU bolus followed by 4000 IU/d) in individuals with greater vitamin D deficiency (25(OH)D < 30 nmol/L)
Trial: 18644685
Drug: Naltrexone 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 12.5 mg once daily for 3 days, 25 mg once daily for 4 days, and 50 mg once daily for 11 weeks, plus placebo sertraline
Trial: 18644685
Drug: Naltrexone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone with sertraline
Trial: 17875198
Drug: Acupuncture +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture + proton pump inhibitor
Trial: 14734123
Drug: Darusentan (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darusentan (mean dose 144 +/- 125 mg/day, dosages of 30 mg, 100 mg, or 300 mg for 3 weeks)
Trial: 25743829
Drug: High-frequency microsatellite
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency microsatellite instability without adjuvant chemotherapy
Trial: 23246249
Drug: 14-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day course of oral doxycycline (Doxy-14)
Trial: 21444113
Drug: Pregabalin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150 to 600 mg/d)
Trial: 12612033
Drug: PAS(10 ms)
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAS(10 ms) under the influence of dextromethorphan (an NMDA receptor antagonist).
Trial: 12612033
Drug: PAS(10 ms)
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAS(10 ms) under the influence of nimodipine (an L-type voltage-gated calcium-channel antagonist).
Trial: 11028833
Drug: Tropisetron (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (5 mg) daily for 28 days
Trial: 8649631
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) - enoxaparin 40 mg/0.4 ml
Trial: 28582271
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral carbohydrate (CHO) loading (800 mL of water containing 100 g of CHO)
Trial: 28582271
Drug: Placebo (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (800 mL of water)
Trial: 22370487
Drug: Expanded workplace
RxNorm normalized name: Allogeneic, ex-vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells - cultured fraction (CF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expanded workplace depression treatment programs
Trial: 22370487
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for major depressive disorder (MDD)
Trial: 22370487
Drug: Detection and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection and treatment of depression among patients with chronic physical disorders
Trial: 22370487
Drug: Early MDD
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early MDD treatment interventions
Trial: 20852963
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of [¹H]MRSI and DCE-MRI
Trial: 15813810
Drug: Nasal steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal steroids (budesonide 400 microg daily)
Trial: 15813810
Drug: Specific allergen
RxNorm normalized name: House dust specific allergen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific allergen immunotherapy (SIT)
Trial: 12154417
Drug: GIK solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK solution therapy
Trial: 19301989
Drug: Oxycodone IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone IR
Trial: 19250295
Drug: Comprehensive school‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive school‐based preventive oral health program
Trial: 18162029
Drug: EE/DRSP (ethinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/DRSP (ethinyl estradiol 30 mug/day plus drospirenone 3 mg/day)
Trial: 8037128
Drug: Atrioventricular junction
RxNorm normalized name: cerliponase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrioventricular junction radiofrequency ablation plus pacemaker therapy (n = 12)
Trial: 8037128
Drug: Pacemaker therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacemaker therapy alone (n = 11)
Trial: 29063853
Drug: Brachytherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brachytherapy plus External Beam Radiation Therapy (EBRT)
Trial: 23064441
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg TXA immediately before CS
Trial: 9109749
Drug: Xanomeline high
RxNorm normalized name: Xanomeline
DrugBank: Xanomeline (DB15357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanomeline high dose (225 mg)
Trial: 8225682
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg b.i.d. misoprostol
Trial: 3512420
Drug: oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral acyclovir alone
Trial: 3512420
Drug: oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral acyclovir plus co‐trimoxazole
Trial: 27282261
Drug: PPI plus
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI plus rebamipide (300 mg/day)
Trial: 27282261
Drug: PPI monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI monotherapy (10 mg/day)
Trial: 25035199
Drug: Hyperfractionation (HFX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionation (HFX) to 79.2 Gy in 66 fractions of 1.2 Gy given twice a day
Trial: 11816915
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with verteporfin
Trial: 8752779
Drug: Pentazocine 30
RxNorm normalized name: pentazocine 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 30 mg before surgical incision (group A)
Trial: 8752779
Drug: Pentazocine 30
RxNorm normalized name: pentazocine 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 30 mg after abdominal incision (group B)
Trial: 8752779
Drug: Pentazocine 60
RxNorm normalized name: pentazocine 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 60 mg after abdominal incision (group B)
Trial: 7096142
Drug: NH4Cl (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NH4Cl (300 mg/kg body wt) to induce acidosis
Trial: 26957103
Drug: Cedar Project
RxNorm normalized name: Cedar oil
DrugBank: Cedar oil (DB10917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cedar Project WelTel mHealth intervention (mobile phone, cellular plan, weekly two-way text messaging, support from Cedar Case Managers)
Trial: 22349946
Drug: Ethanol treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol treatment for 0s (control group) with Adper™ Scotchbond™ Multi‐Purpose (Scotchbond)
Trial: 22349946
Drug: Ethanol treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol treatment for 20s (Group 1) with hydrophobic adhesive
Trial: 22349946
Drug: Ethanol treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol treatment for 60s (Group 2) with hydrophobic adhesive
Trial: 22349946
Drug: Ethanol treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol treatment for three 60s periods (Group 3) with hydrophobic adhesive
Trial: 17714101
Drug: Drug therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapies for neuropathic pain
Trial: 10172792
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil 100 mg twice daily for 5 days
Trial: 10172792
Drug: Phenoxymethylpenicillin 1
RxNorm normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethylpenicillin 1 MIU 3 times daily for 10 days
Trial: 10172792
Drug: Amoxicillin-clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanic acid 500/125 mg 3 times daily for 10 days
Trial: 26387117
Drug: Contact force
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact force (CF)‐guided ablation with a target CF of 20 g
Trial: 22307382
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression therapy (3 h daily for 3 months)
Trial: 22307382
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IPC therapy)
Trial: 3057036
Drug: diltiazem (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem (360 mg/day)
Trial: 29749262
Drug: Oxazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (10 mg every night)
Trial: 26912554
Drug: AST-120 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120 (6 g in three divided doses per day)
Trial: 26912554
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard conventional treatment)
Trial: 10051494
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg orally once daily for 52 weeks
Trial: 15131468
Drug: Lamivudine treatment
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine treatment
Trial: 2147377
Drug: Enalapril maleate
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril maleate 20 mg once daily, increased to 40 mg once daily in 14 patients, with 12.5 mg hydrochlorothiazide added in 5 patients.
Trial: 2147377
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 weeks) followed by enalapril maleate treatment.
Trial: 31425504
Drug: L-5-methyltetrahydrofolate (10.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-methyltetrahydrofolate (10.4 μg/100 ml)
Trial: 31425504
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (10.0 μg/100 ml)
Trial: 28574779
Drug: Higher-dose trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose trastuzumab (HD) 10 mg/kg every 3 weeks
Trial: 28574779
Drug: Standard-of-care (SoC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SoC) trastuzumab 6 mg/kg every 3 weeks
Trial: 9272404
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg ibuprofen
Trial: 12468609
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g of dried mango with 5 g of fat, 5 d/wk for 4 mo
Trial: 12468609
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g of dried mango without fat, 5 d/wk for 4 mo
Trial: 12468609
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule at baseline
Trial: 9618753
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) treatment, cumulative 3.5 mg
Trial: 9098473
Drug: Pellet-Swim-up (SU)
RxNorm normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pellet-Swim-up (SU) treatment
Trial: 9098473
Drug: Centrifugation on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centrifugation on Discontinuous Percoll Gradient (MP) treatment
Trial: 31752000
Drug: Standard level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard level of 22 ± 1 mEq/L (Control)
Trial: 25345731
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion relieving pain
Trial: 21895745
Drug: Seasonal trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal trivalent influenza vaccine followed by two doses of pandemic H1N1 2009 vaccine (Group 1)
Trial: 21895745
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of pandemic H1N1 2009 vaccine followed by simultaneous vaccination of seasonal trivalent vaccine and second dose of pandemic H1N1 2009 vaccine (Group 2)
Trial: 28956169
Drug: Thermal mineral
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal mineral water treatment (n=26)
Trial: 24793941
Drug: 4 Pillars
RxNorm normalized name: BACCHARIS PILULARIS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 Pillars Toolkit and early vaccine supplies
Trial: 20618338
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m2 + Tanespimycin 50 mg/m2
Trial: 843177
Drug: Major role
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Major role therapy (MRT)
Trial: 843177
Drug: Regular medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular medication adherence support (e.g., visiting nurse, long-acting medication)
Trial: 22696580
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for partial seizures
Trial: 18842771
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg dairy calcium supplementation per day for 5 weeks
Trial: 8908381
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (2.7 g/day eicosapentaenoic plus docosahexaenoic acid for 2 months, then 1.7 g/day for 4 more months)
Trial: 6613136
Drug: Fibrinogen cryoprecipitate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen cryoprecipitate, thrombin solution, and factor XIII concentrate used for gluing in suprapubic transvesical prostatectomy
Trial: 16236038
Drug: Fluvoxamine (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (four doses of 100 mg over 2 days)
Trial: 16236038
Drug: Caffeine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (single 250 mg dose)
Trial: 16236038
Drug: Fluvoxamine (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (four doses of 100 mg over 2 days) + Caffeine (single 250 mg dose)
Trial: 2868030
Drug: Diltiazem, 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem, 240 mg/day
Trial: 2152233
Drug: Propranolol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (60 to 240 mg/day)